Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2000

View Archived Issues

First combination monoclonal antibody therapy for chronic HBV shows promise in phase I

Cangene to acquire Chesapeake Biological Laboratories

IntraBiotics reports Q3 R&D progress

CuraGen reports progress in Biogen research collaboration; Gemini Genomics alliance begins

Bristol-Myers Squibb updates investors at healthcare conference

Aviron submits BLA for FluMist

FDA approves once-daily Videx capsules

Scios begins phase I trial with oral p38 kinase inhibitor; preclinical results reported

Discovery awarded fast track SBIR grant for Surfaxin development

Abbott to transfer Gabitril rights to Cephalon

Glaxo Wellcome granted rights to Zambon's ACE/NEP inhibitor

New platinum complex produces CR in over 50% of patients with liver cancer in phase II trial

KRN-7000 as an adjunct to surgical removal of tumors

Low-dose combination of nedaplatin + 5-FU shows promise in esophageal cancer

Cell Therapeutics receives FDA approval to begin PG-TXL clinical trials

Clinical results for entecavir presented at AASLD meeting

Phase III trial of 3M's genital herpes Rx begin

October launch for Rescula, a new docosanoid for glaucoma, in U.S.

CpG-7909 is a safe and effective adjuvant to HBV vaccine, according to early phase I results

Novel diamidoxime prodrug DB-289 highlighted at AAPS meeting

Antiandrogenic antitumor agent VN/87-1 examined for pharmacokinetics in mice

Inhibitors of protein kinases, particularly VEGF-R2 kinase activity, described by GW

Pfizer reports preparation and use of new MMP-inhibitory hydroxamic acids

International patent issued to DuPont for new MEK inhibitors

Tachykinin antagonists from Merck claimed for pain, etc.

New treatments for sexual dysfunction and cardiovascular disorders disclosed by BMS

Novel inhibitors of IMPDH synthesized and tested for biological activity at Vertex

Pyridine- and pyrimidine-based compounds from AstraZeneca for cytokine-mediated disorders

AstraZeneca presents potential new antirhinitis and antiasthma agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...